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Even in the era of successful combination antiretroviral therapy (cART), co-infection of Hepatitis C virus (HCV) remains
one of the leading causes of non-AIDS-related mortality and morbidity among HIV-positive individuals as a
consequence of accelerated liver fibrosis and end-stage liver disease (ESLD). The perturbed liver microenvironment
and induction of host pro-inflammatory mediators in response to HIV and HCV infections, play a pivotal role in
orchestrating the disease pathogenesis and clinical outcomes. How these viruses communicate each other via
chemokine CCL2 and exploit the liver specific cellular environment to exacerbate liver fibrosis in HIV/HCV co-infection
setting is a topic of intense discussion. Herein, we provide recent views and insights on potential mechanisms of CCL2
mediated immuno-pathogenesis, and HIV-HCV cross-talk in driving liver inflammation. We believe CCL2 may potentially
serve an attractive target of anti-fibrotic intervention against HIV/HCV co-infection associated co-morbidities.
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Liver fibrosis is an immuno-pathological event associated
with chronic inflammation caused by liver injury and/or
infection by the viruses. Uncontrolled fibrosis may pro-
gress to severe forms of the disease, such as liver cirrhosis
(CH) and hepato-cellular carcinoma (HCC). Globally, ~
35 million people are infected with HIV out of which
20-30% individuals are co-infected with HCV [1]. The
prevalence of co-infection is higher in some key pop-
ulations especially people who inject drugs due to the
shared mode of transmission [2]. Although significant
achievements have been made in reducing HIV/AIDS-re-
lated mortality and morbidity through successful imple-
mentation of cART, HCV-related liver disease remains a
major therapeutic challenge to those co-infected with
this virus. One of the major impact of HCV coinfection
is the persistent low CD4+ T cell counts in HIV/HCV co-
infected compared to HIV mono-infection individuals
[3]. Conversely, co-infection of HIV adversely affects the* Correspondence: awansari@um.edu.my; adeeba@ummc.edu.my
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unless otherwise stated.natural history of HCV infection by multiple ways in-
cluding: rapid virus replication, accelerated fibrosis and
poor response to antiretroviral therapy [3]. Although, cel-
lular immune responses elicited against HCV spontan-
eously clear the virus in more than 30% of infected
individuals [4,5] but the majority of them fail to do so and
end in chronicity.
HCV is a hepatotropic RNA virus that causes hepatitis,
CH and HCC [6]. Given that HCV-specific CD8 + T cells
are critical for virus control, non-specific immune re-
sponse by innate effector NK cells, constituting around
30% of intrahepatic lymphocytes (IHL), too contribute to
virus persistence and liver pathology [7]. However, in
HIV/HCV co-infection scenario, the systemic immune
dysfunction and CD4+ T cell depletion associated with
HIV, remains the major factor in HCV persistence and
chronic liver inflammation. Growing body of evidence
have supported accelerated liver fibrosis and organ failure
in HIV/HCV co-infected compared to HCV mono-infected
individuals [8] especially in those with CD4 T cell
count below 200 cells or at advanced stage of the HIV
disease [9]. Although the cART regimen significantly re-
stores CD4+ T cells in HIV mono-infection but the dataThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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ported CD4+ T cell recovery following 4-years of HAART
[10] while other does not [9,11]. Further, HCV co-
infection has been shown to negatively impact CD4+
T cell reconstitution following HAART [12]. Therefore,
these studies suggest high mortality rate among the HCV-
coinfected individuals as a consequence of severe liver
disease, rather than AIDS-related illness.
CCL2, also known as monocyte chemo-attractant
protein-1 (MCP-1), is a small molecular weight protein
of C-C chemokine family with strong chemotactic be-
haviour toward monocytes, NK cells and CD4+ T cells
[13,14]. Many cell types including monocytes, dendritic
cells, endothelial cells (EC) and epithelial cells produce
CCL2 in response to a variety of microbial insults and
pro-inflammatory stimuli. Apart from leukocyte recruiting
properties, role in immune homeostasis and human dis-
eases such as cancer, infection and autoimmunity is well
appreciated [15-18]. The data from ours and others la-
boratories strongly suggest CCL2 a supporter of HIV rep-
lication and disease progression through multiple ways
(see section CCL2 supports HIV replication and disease
progression). However contribution to hepatitis virus trig-
gered chronic liver inflammation and progression to fibro-
sis, has recently been described both in humans and
murine models of hepatitis [19-21]. CCL2 and its receptor
display a varied expression and are closely linked with
liver disease. For example, in non-alcoholic steatohepatitis,
both CCL2 and CCR2 levels are up-regulated, causing
macrophage infilteration resulting in that eventually leads
to inflammation, fibrosis, steatosis and accumulation in
adipose tissues [22].
Fibrosis is a key event associated with liver injury trig-
gered by virus and other inflammatory agents. It is char-
acterized by excessive deposition of extra-cellular matrix
(ECM) components including collagens, fibronectin and
proteoglycan into Desse and reduced levels of tissue in-
hibitor of metalloproteinase (TIMP-1), an ECM remov-
ing matrix metalloproteinase (MMP) [23]. Human liver
constitutes a complex cellular environment comprised of
hepatocytes, hepatic stellate cells (HSC), macrophage
(Kupffer cell) and T cell subsets. HSC has been consid-
ered as the major contributor of liver fibrosis by produ-
cing inflammatory mediators and substrates required for
fibrogenesis [24,25]. In this regard, HCV infected hepa-
toma cell derived supernatant has been shown to trigger
production of most potent pro-fibrotic molecule TGF-β
by HSC [26]. Notably, both HIV and HCV induce an
array of inflammatory cytokines and chemokines to regu-
late pathogenesis of relevant diseases. Some of these
include, cytokine TNF-α, TGF-β Interferons (IFNs) and
ROS, and chemokine CCL2 (MCP-1), CCL3 (MIP1-α),
CCL4 (MIP-1β), CCL5 (RANTES), CXCL8 (IL-8), CXCL9
(MIG), CXCL10 (IP-10) and CXCL11 (I-TAC) [22,27]. Todiscuss the contribution of individual molecule in hepatic
fibrosis is beyond the scope of this review thus herein, we
focus on one of the most relevant mediator CCL2. How-
ever a comprehensive analysis of chemokine-chemokine
receptor in liver disease is described elsewhere [22].
In addition to liver-resident macrophage (Kupffer cell),
human hepatic macrophages can be divided into ‘classical’
CD14++ CD16− and ‘non-classical’ CD14+ CD16+ subsets.
The later frequency found to be preferentially higher in
liver fibrosis and HIV infection [28,29]. The circulating
monocytes originated from the bone marrow are re-
cruited into the liver in response to chemokines produced
either by virus insult or injury. That later differentiate
into functional liver macrophages as demonstrated in
bone marrow and liver transplant mice models [30].
Functionally Kupffer cells are competent to sense the
danger signals via TLR receptors and trigger release
of inflammatory mediators including CCL2. On other
hand, infiltrating monocyte-derived macrophages are
found to be mostly linked to fibrosis and chronic inflam-
mation. In this regard, experimental mouse model of fi-
brosis has demonstrated influx of inflammatory Ly-6Chi
monocytes into the liver in response to CCL2 [31] and
that letter differentiate to Gr1+ inflammatory subset, an
equevalent of human CD14+CD16+ cells.
HIV/HCV co-infection immuno-pathogenesis
HCV-induced liver injury and subsequent progression to
fibrosis is an immuno-pathological event governed by
complex virus- host interactions [3,32]. Though HCV-
specific infiltrating T cells are thought to be the major
contributor of liver injury but in HIV co-infection set-
ting, it is less likely that these functionally impaired cells
can accelerate liver pathology. Accumulating body of evi-
dence suggest hepatocytes and other liver cells can be in-
fected and may serve as HIV reservoir [33-36], thus can
play a regulatory role in shaping the liver specific immune
responses. Interestingly, HIV and HCV can interact and
reciprocally affect the natural history of each other. The
potential mechanisms of HCV impact on HIV disease
progression is not fully understood. One study reported
activation of HIV-long-terminal repeat (LTR) promoter
by HCV in transfected hepatocytes [37], while others
observed increased risk of mortality among HIV/HCV
co-infected individuals despite successful cART adminis-
tration [9,11] as discussed in introduction part. On other
hand, HIV can infect and/or activate liver cells via co-
receptor CCR5 and CXCR4 to accelerate HCV-induced
hepatic fibrosis [36]. In addition to virus, HIV purified
proteins such as TAT [38], gp160 [39] and accessory
vpu [40] can contribute to hepatic fibrosis by induction
of pro-fibrotic cytokine TGF-β. Further HIV TAT has also
been shown to enhance HCV replication via chemokine
CXCL-10 [41]. However, depletion of Kupffer’s cell (KC)
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disease progression in HIV/HCV co-infected individ-
uals [42]. Taken together above studies suggest the recip-
rocal effects and consequences of viral interactions on the
liver injury.
Immuno-pathology of HIV/HCV co-infection associated
liver disease is multi-factorial [43]. Several hypothesis of
HIV-mediated acceleration of liver injury have been de-
scribed in HIV/HCV co-infection [44,45]. This includes
HIV-associated immune dysfunction, defective antiviral
CD8+ T cells responses and reduced CD4/CD8 ratio. The
perturbed cellular ratio may contribute to liver damage, as
higher proportion of CD8+ T cells are suggested relatively
more fibrogenic than CD4+ T cells [46]. Another import-
ant event that may contribute to liver fibrosis is the direct
activation of HSC by HIV gp120 or via pro-inflammatory
mediators induced in response to infection [45,47]. More-
over, the potential mechanisms by which both the patho-
gens can contribute to liver damage may include, (1) HIV
and HCV-triggered production of reactive oxygen species
(ROS) that signals via c-Jun N-terminal kinase (JNK),
extracellular signal-related kinase (ERK) and p38 mito-
gen activated protein kinase (p38MAPK) through NFkB
to up-regulate TGF-β production and decrease of matrix
metaloprotease-3 (MMP3) [48,49]. (2) Stimulation of
HCV-infected hepatocytes by HIV gp120 to induce HCV
replication via TGF-β [49]. (3) Induction of hepatocyte
apoptosis by HIV and HCV to trigger pro-fibrotic activity
of HSC as observed in both HIV/HBV and HIV/HCV co-
infections [50-53].
Impact of HIV-associated microbial translocation on liver
fibrosis
Immune activation is a hallmark of advanced HIV dis-
ease associated with chronic T cells activation and sus-
tained plasma levels of pro-inflammatory cytokines.
Systemic immune dysfunction and mucosal CD4+ T
lymphocytes depletion from lymphoid tissues of gastro-
intestinal (GI) tract of HIV positive individuals are
thought to be the major driving force behind this event.
The mucosal permeability and subsequent microbial
translocation leads to production of high levels of soluble
(s) CD14, sCD163 and IL-6 by activated macrophages in
response to microbial product, lipopolysaccharide (LPS)
[54]. In addition to HIV, this phenomenon has also been
observed in HIV/HCV and HIV/HBV co-infection, where
a higher levels of plasma LPS, sCD14 were detected in
coinfected than mono-infected individuals [54-56]. As
liver cells are constantly exposed to gut-derived LPS via
portal circulation, there is a high likelihood of KC and
HSC activation to produce inflammatory mediators such
as TNF-α, TGF-β and CCL2 [25,57]. Under such situation,
KC has been attributed with larger role since binding of
LPS to their TLR4 releases large amount of pro-fibroticmolecule TGF-β, TIMP-1 and collagen type 1 [58] to set
the stage for initiation of fibrosis (Figure 1).
The association of microbial translocation and contri-
bution of LPS to liver inflammation in HIV/HCV co-
infection setting has recently been recently appreciated
[59-61]. These studies suggest LPS a key component ac-
count for rapid disease progression and organ failure. In
addition to microbial products, a high quantity of innate
anti-viral cytokine IFN-α and associated T cell activation,
immensely contribute to virus replication and CD4+ T
cell death in HIV/HCV co-infected than HIV mono-
infected individuals [62,63]. Given the occurrence of mi-
crobial translocation in both HIV-mono and HIV/HCV
co-infections, strategies should be developed to reduce
overt immune activation in order to contain progressive
liver diseases.
CCL2 supports HIV replication and disease progression
Host chemokines induced by HIV may either support
or inhibit virus replication. For example, C-C chemokine
CCL3, CCL4, CCL5 and C-X-C chemokine CXCL12
(SDF-1α) has been described as potent inhibitors of R5 and
R4 HIV strains by binding to their respective co-receptors
CCR5 and CXCR4 [64-66]. Thus, early production of the
above chemokines in lymph nodes can be beneficial in con-
taining the virus spread. In this context, researcher have
succeed in developing of CCR5 analogue, AOP-RANTES
and antagonist Maraviroc [67,68], the latter has now pro-
gressed to clinical practice. Unlike HIV inhibitory C-C
family members, CCL2 is thought to support HIV replica-
tion by multiple ways [69-72] indicating a functional di-
chotomy within C-C chemokine family members.
A number of clinical data including ours have shown
elevated CCL2 in the serum [70,71] and cerebrospinal
fluid (CSF) [73] of HIV subjects that significantly corre-
lates with plasma viral load. Further, we reported a dif-
ferential CCL2 expression by HIV-infected viremic and
aviremic individuals, suggesting active virus replication
leads to greater CCL2 induction and thus diseases severity
compared to suppressed one [70,71]. The potential mech-
anisms of CCL2 mediated enhanced HIV pathogenesis
has been described elsewhere [72,74]. This includes, (1)
the positive feed-back loop model where recruitment of
HIV permissive CCR2+ monocytes/macrophages and
CD4+ T cells at the site of infection for new round of rep-
lication [70,75]. (2) induction of co-receptor CXCR4 on
resting CD4+ T cells [76]. (3) up-regulation of CXCR4
through IL-4 [77] (4) differentiation of helper T cell (Th0)
cells to type-2 helper T cells (Th2) [78], a hallmark of
HIV/AIDS. (5) enhancement of HIV virion release [79]. A
summary of above mechanisms in conjunction with HCV-
coinfection is described later in the article (Figure 2).
Evidence of CCL2 production is also observed in
































Figure 1 Adverse effects of HIV on HCV replication and liver fibrosis. HIV-associated systemic immune dysfunction and microbial translocation
are the critical factors that drive HCV replication and fibrosis in HIV/HCV co-infected individuals. Depletion of CD4+T cells in conjunction with Th17 cells
causes microbial translocation that dispenses their products in the blood circulation. Activation of Kupffer cells via TLR4 produces numerous fibrotic
mediators including TGF-β, TIMP-1 and type-1 collagen. Taken together both systemic immune dysfunction and microbial translocation contribute to
enhanced HCV replication and liver fibrosis.
Figure 2 CCL2-mediated synergistic effects of HIV/HCV co-infection on liver fibrosis. Proposed model explains migration of HIV into the
liver to infect or activate Kupffer cells, hepatocytes and HSCs directly or indirectly via ROS and TGF-β, to create CCL2 rich inflammatory milieu.
CCL2 may act on HSC in a positive feed-back loop manner to accelerate fibrosis via myofibroblast and collagen synthesis. Elevated CCL2 in the
liver could also recruit HIV permissive CD4+ T cells and monocytes into the liver for next round of virus replication in a positive feed-back loop
manner. This leads to persistence of a high HIV viremia. In addition, elevated CCL2 can polarize helper T cells (Th0) cells into IL-4 and IL-10
secreting Th2 phenotype, a strong determinant HIV disease progression. Further, CCL2 can induce CD4+ T cells to express higher levels of
CXCR4, an HIV co-receptor. Overall this scheme depicts how a complex cellular interactions and virus cross-talks via CCL2 can potentially
drive hepatic fibrosis HIV replication in HIV/HCV co-infection scenario.
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the notion that CCL2 is indeed an important and relevant
factor in HIV infection. Further, considering one of the
most common HIV/Mtb co-infection scenario, CCL2 is
believed to exacerbate the disease pathogenesis by ad-
versely affecting the natural history of both the pathogens
[81]. Although CCL2 is mostly produced by monocytes in
the peripheral blood, the inflammatory CD14+CD16+
monocyte subset has been found to be the major source
of CCL2 in HIV-infected individuals [29] as well as in liver
fibrosis [28].
CCL2 accelerates HCV-induced liver fibrosis
A series of inflammatory mediators are up-regulated
during HCV infection and associated liver diseases such
as CH and HCC [82-84]. Some of these mediators are,
reactive oxygen species (ROS), CCL2, IL-6, CXCL8 and
CXCL10 released by activated KC and hepatocytes [46].
In addition to these, HCV induced early interferons
(IFNs) production by KC triggers production of CCL2.
High levels of CCL2 may recruit CCR2+ leukocytes in-
cluding; monocytes, NK cells, CD4+ T cells into the liver
to start inflammatory reactions [85,86]. Compelling clin-
ical evidence suggest an increased CCL2 and its receptor
CCR2 mRNA transcripts in HCV infected liver specimens
[87,88] that positively correlates with disease severity [89].
The relevance of CCL2 in liver diseases was further sup-
ported by studies on liver transplantation [90], HCC [91]
and fibrosis regression with pharmacological inhibitor of
CCL2 in mice [21]. Thus, above clinical studies and ex-
perimental models clearly suggest CCL2 a key mediator of
hepatic fibrosis and their potential blocking may offer im-
proved clinical outcome.
A detailed association between chemokines and liver dis-
eases has been described elsewhere [22]. Some of the im-
portant chemokines and their cognate receptors relevant
to HCV and fibrosis include, CCL2 and receptor CCR2 on
monocyte/macrophages and HSC; CCL3, CCL4, CCL5
and their receptor CCR1 and CCR5 on natural killer (NK),
CD8 and Th1 cells; CXCL9, CXCL10 CXCL11 and recep-
tor CXCR3 on NK, CD8, Th1 and HSC. Further example
chemokine mediated liver injury includes, persistence of
elevated serum CXCL-10 and CXCL8 levels in the recipi-
ents following liver transplantation, who developed higher
hepatic necro-inflammation and fibrosis [92]. Beside regu-
lating leukocytes trafficking, CCL2 possess strong angio-
genic characteristics as an inducer of VEGF expression
[46] shown by infiltrating macrophages in mouse model
of inflammatory associated progressive fibrosis [20].
Further, sustained levels of CCL2 has been considered
critical in both triggering liver injury and subsequent de-
velopment of fibrosis and thus, can serve as predictor of
progression towards cirrhosis [19]. It is the cross-talk be-
tween HSC and HCV-infected hepatocytes that deriveimmune-pathogenesis and onset of fibrosis [93] poten-
tially via an autocrine CCL2 loop [94-97]. Apart from
HCV infection of hepatocytes, viral core protein NS5A
has been found to increase ROS via mitochondrial in-
sult [98]. ROS activate KC to release CCL2 that trans-
forms HSC to into pro-fibrogenic myofibroblast to secrete
α-smooth muscle actin and fibriller collagens I and
III (Figure 2). Moreover, host genetic make-up of HCV-
infected individuals can greatly influence the outcome
of the liver diseases. For example, CCL2 polymorph-
ism is found to be associated with significantly higher
hepatic expression specifically in those individuals with
advance liver fibrosis [99].
Mechanisms of CCL2-mediated HIV:HCV interactions in
liver fibrosis
The natural infection of both HIV and HCV is affected
by their presence in the same host. Compared to HCV, the
effect of HIV on HCV infection is considered more dele-
terious (described in mechanisms of HIV/HCV immuno-
pathogenesis section). Given that CCL2, an important
factor associated with pathogenesis of both the viruses, it
is important to understand the impact on liver cellular
microenvironment and virus-triggered hepatic fibrosis.
We herein summarize the potential mechanisms (Figure 2)
that includes, (1) both HCV and HIV can induce release
of CCL2 by KC, hepatocyte and HSC, either directly or in-
directly via TGF-β and ROS produced by hepatocytes
[48,49]. (2) This up-regulates CCL2 levels in the liver to
recruit that CCR2+ monocytes and CD4+ T cells from the
hepatic portal blood to the site of infection in a feed-back
loop manner, resulting in rapid HIV replication and subse-
quent increase in viremia. (3) CCL2 can also act on HSC
in a positive feed-back loop [36] to transform acti-
vated HSC into myofibroblast and collagen synthesis. In
addition to their role in liver fibrosis, it is argued that high
levels of CCL2 can severely affect the course of HIV infec-
tion by up-regulating HIV-co-receptor CXCR4 on CD4+ T
cells [76] and polarization of helper T cells towards Th2
phenotype [78], a hallmark of progressive HIV disease. In
summary there is complex virus-virus and host-virus inter-
action in HIV/HCV co-infection, and CCL2 is certainly an
important factor that mediates these above cross-talks.
Therapeutic management of HIV/HCV co-infection
Significant reduction in HIV associated mortality and
morbidly has been achieved with the advent of cART.
However, co-infection of HCV has posed major clinical
challenge as proportion of HIV/HCV co-infected indi-
viduals develop CH and HCC. Generally the treatment
of HCV mono-infection involves 24–48 weeks of antivi-
rals consisting pegylated interferon-alpha (pegIFN-α)
plus ribavirin (RBV) [9]. A regimen that also found to
be effective in cases of HIV/HCV-coinfections, achieving
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25-50% with cure rate of 70-80% for HCV geneotype 2
and 3 and relatively reduced SVR of 18-38% for the
genotype 1 and 4 infections [100]. Although, pegIFN/
RBV therapy has significantly reduced the liver associated
co-morbidities in co-infected individuals, the adverse ef-
fect on central nervous system (CNS) and hepatic toxicity
has led to a decline in treatment uptake as reported in
EuroSIDA cohort studies [101]. Therapeutic treatment of
HCV/HIV was tremendously boosted with the advent
of multiple new direct acting antivirals (DAA) includ-
ing HCV protease and polymerase inhibitors, and HCV
NS3-4A inhibitor telaprevir and boceprevir in 2011 [100]
and the data from pilot studies demonstrated significantly
improved the outcome compared to standard pegIFN/
RBV alone [102,103]. However, the drug is not in use
anymore potentially due to drug-drug interaction be-
tween inhibitors of HIV and HCV, frequent adverse effect
such toxicity of liver, CNS, high cost and pill burdens.
Now, the European Association for the Study of the Liver
(EASL) recommends a new IFN-free therapy against HIV/
HCV coinfection that includes sofosbuvir plus daclatasvir/
simprevir/ledipasvir. The newly developed AbbVie 3D
regimen, consists of combination of HCV NS3/4A prote-
ase inhibitor ABT-450 with ritonavir, the NS5A inhibitor
ombitasvir (ABT-267), and the NS5B RNA polymerase in-
hibitor dasabuvir (ABT-333) with or without ribavirin
have shown high cure rate in phase III clinical trials, and
expected to be in clinical practice very soon.
In addition to antivirals, chemokine and chemokine re-
ceptor based blockers and antagonists could provide an
attaractive immuno-therapeutic approach against HIV/
HCV co-infection associated liver diseases. This startegy
has proven success in HIV infection, where CCR5 antag-
onist, Maraviroc effectively suppress HIV replication in
infected individuals [68]. Given the immune-therapeutic
potentials of CCL2 blockade against breast and prostate
cancer [15,16], the CCL2-CCR2 target based approach may
prove beneficial in reducing HIV/HCV co-morbidities. In
this regard, CCR2 antagonist, CCX140 and inhibitor BMS-
741672, has already been tested for Phase II studies of
liver fibrosis. While, NOX-E36, a CCL2 blocker [21]
and the dual CCR2/CCR5 blocker, Ceniceriviroc (Tobira
Therapeutics Inc, San Francisco, CA) have shown appreci-
ating results in rodent models of fibrosis. Given that some
of the above tests in animals found to be successful, the
human test is yet to prove their efficacy. Therefore, more
efforts needed to understand the immune-pathological
events to employ above approach to treat infection associ-
ated liver injury.
Conclusion
The majority of the literature supports the notion that
mortality among HIV/HCV co-infected individuals occursdue to liver failure rather than AIDS-related complica-
tions. Since fibrosis is an immune-pathological event it
would wise to target those factors which are induced by
both the viruses and are critical in liver diseases severity.
CCL2 is one such pro-inflammatory molecule that could
be targeted for anti-inflammatory strategies since CCL2
blockade strategy has already been implemented clinically
in breast and prostate cancer immune-therapy [15,16].
Further understanding of intra-hepatic inflammatory net-
work, microbial translocation and metabolic factors hold
the promise for developing new therapeutic approaches.
Perhaps humanized animal models supporting HIV and
HCV infections can provide more mechanistic and thera-
peutic answers to this problem.
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